Despite having its initial roots in active pharmaceutical ingredients, generics and later biosimilars, Dr Reddy’s is increasingly exploring new ventures in the innovative arena. The firm has more recently branched out into areas including nutraceuticals and immuno-oncology new chemical entities, is placing a greater emphasis on contract development and manufacturing activities, and is exploring new frontiers in digital health and cell and gene therapy.
Speaking to Generics Bulletin in the first part of an exclusive two-part interview, CEO Erez Israeli has set out how...
